Coverage Initiated for Predictive Oncology via NetworkNewsWire
September 19 2019 - 8:30AM
via NetworkWire – Predictive Oncology (NASDAQ: POAI), an innovative
company focused on the use of data and artificial intelligence (AI)
to develop personalized cancer therapies and improve patient
outcome, today announces it has selected the corporate
communications expertise of NetworkNewsWire ("NNW").
Through its Helomics, TumorGenesis and Skyline Medical
subsidiaries, Predictive Oncology’s portfolio of assets includes: a
database of clinically validated historical and outcome data from
patient tumors; an in-house Clinical Laboratory Improvement
Amendments (CLIA)-certified lab; a “smart” patient-derived tumor
profiling platform; an in-house bioinformatics artificial
intelligence (AI) platform; a new computerized approach growing
tumors in the lab to rapidly develop patient specific treatment
options, and; an FDA-approved fluid collection and disposal
system.
Using these resources, and in collaboration with key players in
the pharmaceutical, diagnostic and biotech industries, Predictive
Oncology is working to determine the best pathways for more
individualized and effective cancer treatment. In addition, the
Company’s partnership with NNW provides heightened awareness of its
progress and operations among shareholders.
NNW is a multifaceted financial news and publishing company that
delivers a new generation of social communication solutions, news
aggregation and syndication, and enhanced news release services.
NNW’s strategies help public and private organizations find their
voice and build market visibility. As part of the Client-Partner
relationship with Predictive Oncology, NNW will leverage its
investor-based distribution network of over 5,000 key syndication
outlets, various newsletters, social media channels, blogs, and
other outreach tools to generate greater brand awareness for the
company.
“Predictive Oncology strategically utilizes the power of AI to
develop effective, customizable treatments in the fight against
cancer,” states Sherri Franklin, Director of Client Solutions for
NNW. “As the company focuses on expanding its market reach, we will
execute a corporate communications campaign that places its
strategy and accomplishments in front of the investment
community.”
About Predictive Oncology Inc.
Predictive Oncology (formerly Precision Therapeutics Inc.)
(Nasdaq: POAI) operates through its three business units, Helomics,
TumorGenesis and Skyline Medical. Helomics applies artificial
intelligence to its rich data gathered from patient tumors to both
personalize cancer therapies for patients and drive the development
of new targeted therapies in collaborations with pharmaceutical
companies. Helomics’ CLIA-certified lab provides clinical testing
that assists oncologists in individualizing patient treatment
decisions, by providing an evidence-based roadmap for therapy. In
addition to its proprietary precision oncology platform, Helomics
offers boutique CRO services that leverage its TruTumor™,
patient-derived tumor models coupled to a wide range of multi-omics
assays (genomics, proteomics and biochemical), and an AI-powered
proprietary bioinformatics platform (D-CHIP) to provide a tailored
solution to its clients’ specific needs. Predictive Oncology’s
TumorGenesis subsidiary is developing a new rapid approach to
growing tumors in the laboratory, which essentially “fools” cancer
cells into thinking they are still growing inside a patient. Its
proprietary Oncology Discovery Technology Platform kits will assist
researchers and clinicians to identify which cancer cells bind to
specific biomarkers. Once the biomarkers are identified they can be
used in TumorGenesis’ Oncology Capture Technology Platforms which
isolate and help categorize an individual patient’s heterogeneous
tumor samples to enable the development of patient specific
treatment options. Helomics and TumorGenesis are focused on ovarian
cancer. Predictive Oncology’s Skyline Medical division markets its
patented and FDA cleared STREAMWAY System, which automates the
collection, measurement and disposal of waste fluid, including
blood, irrigation fluid and others, within a medical facility,
through both domestic and international divisions. The company has
achieved sales in five of the seven continents through both direct
sales and distributor partners. For more information, please visit
www.predictiveoncology.net.
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content
distribution company that provides (1) access to a network of wire
services via NetworkWire to reach all target markets,
industries and demographics in the most effective manner possible,
(2) article and editorial syndication to 5,000+ news outlets, (3)
enhanced press release services to ensure maximum impact, (4)
social media distribution via the Investor Brand Network (IBN) to
nearly 2 million followers, (5) a full array of corporate
communications solutions, and (6) a total news coverage solution
with NNW Prime. As a multifaceted organization with an extensive
team of contributing journalists and writers, NNW is uniquely
positioned to best serve private and public companies that desire
to reach a wide audience of investors, consumers, journalists and
the general public. By cutting through the overload of information
in today’s market, NNW brings its clients unparalleled visibility,
recognition and brand awareness. NNW is where news, content and
information converge.
For more information, please visit:
https://www.NetworkNewsWire.com.
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications:
NetworkWire (NW) New York, New York www.NetworkNewsWire.com
212.418.1217 Office Editor@NetworkWire.com
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024